Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.51 |
| ▸ | ACACA | Q13085 | 7/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31334655 | 0.91 | SYK (0.47) | ACACBACACADRD2SYKCYP1A2 | |
| SCHEMBL31333474 | 0.91 | SYK (0.47) | ACACBACACADRD2SYKCYP1A2 | |
| SCHEMBL13668666 | 0.90 | SYK (0.57) | ACACBACACADRD2SYKCYP1A2 | |
| SCHEMBL13666981 | 0.90 | SYK (0.57) | ACACBACACADRD2SYKCYP1A2 | |
| SCHEMBL6194352 | 0.87 | KMT2A (0.53) | ACACBACACADRD2SYKCYP1A2 | |
| SCHEMBL6194348 | 0.87 | KMT2A (0.53) | ACACBACACADRD2SYKCYP1A2 | |
| SCHEMBL3261676 | 0.85 | ALDH1A1 (0.59) | ACACBACACADRD2SYKKMT2A | |
| SCHEMBL3261678 | 0.85 | ALDH1A1 (0.59) | ACACBACACADRD2SYKKMT2A | |
| SCHEMBL3946631 | 0.83 | ALDH1A1 (0.56) | ACACBACACADRD2SYKATM | |
| SCHEMBL3946595 | 0.83 | ALDH1A1 (0.56) | ACACBACACADRD2SYKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | ACACB 1522/4885ACACA 2148/4885DRD2 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.